KemPharm (KMPH) buyers of 2000 May $10 calls for $3.30 to $3.70 today with IV30 up 7.3%, a large trade for a small cap and a name that has seen 5950 February $10 calls accumulate in open interest and also seen buyers in January 2022 call strikes. KMPH is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary Ligand Activated Therapy, or LAT, technology. Its candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder, or SUD, and idiopathic hypersomnia, or IH. KMPR shares have started to work out of a large rounded base the last two weeks and traded up above $15 earlier this year. KMPH has a $335M market cap and trades just 2.55X Cash with revenues seen at $28.5M in 2021 and rising to $63.7M in 2023. KMPH has not seen any analyst coverage.